Dermatomyositis (DM)
6
2
3
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
17%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (6)
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical Parameters
Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases